Agenus Publishes Ovarian Cancer Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2025
0mins
Should l Buy AGEN?
Agenus announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab in The Journal for ImmunoTherapy of Cancer. In this heavily pretreated population, BOT+BAL demonstrated clinically meaningful activity and durable benefit in women with treatment-refractory ovarian cancer, a population with few remaining options. The combination achieved a 23% overall response rate and 31% clinical benefit rate, including durable responses with a median duration of 9.7 months. Median overall survival reached 14.8 months, with an estimated of 75% of patients alive at 12 months. These findings build on results from the broader C-800-01 dataset presented at ESMO 2025, where BOT+BAL showed activity across multiple refractory solid tumors. Collectively, these data reinforce the potential of BOT+BAL to generate meaningful immune responses in cancers historically considered unresponsive to immunotherapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGEN
Wall Street analysts forecast AGEN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.240
Low
23.00
Averages
23.00
High
23.00
Current: 3.240
Low
23.00
Averages
23.00
High
23.00
About AGEN
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agenus Hosts 2026 Stakeholder Webcast on Immunotherapy Progress
- Immunotherapy Progress: Agenus will host a webcast on March 31, 2026, focusing on the advancements of botensilimab and balstilimab, aiming to enhance treatment options for patients with historically treatment-resistant cancers, showcasing the company's ongoing innovation in immuno-oncology.
- Clinical Data Insights: Chief Medical Officer Steven J. O'Day will discuss the durability and consistency of BOT+BAL across various tumor types, highlighting how these data inform ongoing development and later-stage trials, indicating the company's potential in treating refractory cancers.
- Patient Access Programs: Kamel Djazouli, Head of Medical Affairs, will provide updates on Agenus' global access programs, particularly the AAC and Named Patient Programs in France, demonstrating how the company supports patients with limited treatment options, thereby enhancing its market competitiveness.
- Strategic Priorities: Founder and CEO Garo H. Armen will outline key priorities for 2026, emphasizing the urgency of advancing the BOT+BAL program to improve patient quality of life through innovative treatment solutions.
See More
Agenus Introduces Novel Immunotherapy to Extend Survival
- Innovative Immunotherapy: Agenus announced that preliminary results of the BOT and BAL combination therapy for microsatellite stable colorectal cancer will be presented at the 2026 AACR Annual Meeting, aiming to extend patient survival by reducing reliance on chemotherapy, showcasing the company's cutting-edge exploration in cancer immunotherapy.
- Clinical Trial Expansion: The BBoPCO study is the first trial assessing BOT+BAL in patients without liver, bone, or brain metastases, marking a significant shift towards early application of immunotherapy, which is expected to improve patient response and quality of life, addressing the urgent need for new treatment options.
- Market Demand: Colorectal cancer remains a leading cause of cancer-related deaths globally, with rising incidence among younger populations, and the severe side effects of traditional chemotherapy regimens highlight the critical market significance of introducing new therapies.
- Drug Mechanism: Botensilimab, as an enhanced anti-CTLA-4 antibody, combined with the PD-1 inhibition of balstilimab, aims to activate the immune system targeting traditionally
See More
Agenus Surpasses Earnings and Revenue Expectations
- Earnings Beat: Agenus reported earnings of $0.56 per share, significantly exceeding the Zacks consensus estimate of a loss of $1.27 per share, and improving from a loss of $2.04 per share a year ago, indicating a strong recovery in profitability that is likely to boost investor confidence.
- Significant Revenue Growth: The company posted revenues of $34.2 million for the quarter, surpassing the Zacks consensus estimate of $29.3 million and reflecting a 27.5% increase from $26.84 million a year ago, demonstrating sustained market demand in the biopharmaceutical sector.
- Cautious Future Outlook: Although Agenus has surpassed consensus EPS estimates twice in the past four quarters, management's commentary on future earnings expectations will be crucial for stock price movements; currently, the Zacks Rank is 3 (Hold), suggesting performance may align with the market in the near term.
- Industry Ranking Impact: The Medical - Biomedical and Genetics industry, where Agenus operates, is currently ranked in the bottom 42% by Zacks, which could negatively affect the company's stock performance, prompting investors to monitor overall industry trends for potential impacts on future performance.
See More
Agenus Expands Global Early Access Programs for BOT+BAL
- Expansion of Early Access Programs: Agenus has received over 200 physician inquiries across more than 30 countries, recognizing approximately $4.2 million in initial program revenue, which not only enhances patient treatment opportunities but also strengthens the company's influence in the global market.
- Clinical Data Support: The BOT+BAL combination demonstrated a 42% two-year overall survival and approximately 21 months median survival in heavily pretreated microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients, indicating its potential in difficult-to-treat cancers.
- Initiation of BATTMAN Phase 3 Trial: Agenus has launched the first global Phase 3 registrational trial for the CTLA-4/PD-1 combination in MSS mCRC, expected to enroll 830 patients, aimed at supporting future regulatory submissions and further solidifying its market position.
- Zydus Collaboration Strengthens Infrastructure: The strategic collaboration with Zydus Lifesciences provides Agenus with $91 million in capital and dedicated biologics manufacturing capacity, ensuring clinical development and commercial supply of BOT+BAL, thereby enhancing the company's financial health.
See More
Agenus to Announce Q4 Earnings on March 16
- Earnings Announcement: Agenus (AGEN) is set to release its Q4 2023 earnings on March 16 before market open, with consensus EPS estimate at -$1.30 and revenue estimate at $28.1 million, reflecting a 4.7% year-over-year growth.
- Historical Performance Review: Over the past two years, Agenus has only beaten EPS estimates 25% of the time and revenue estimates 38% of the time, indicating significant volatility in its performance and suggesting investors should proceed with caution.
- Estimate Revision Dynamics: In the last three months, there have been no upward revisions to EPS estimates, with one downward revision, while revenue estimates also saw no upward revisions and two downward revisions, reflecting a cautious market outlook on the company's future performance.
- Collaboration and Expansion: Agenus recently received a $20 million payment under its collaboration with Zydus Life Sciences, highlighting its proactive efforts in global manufacturing expansion and patient access initiatives, which may support future performance.
See More
GSK's Arexvy Vaccine Label Expansion Approved by FDA
- Vaccine Label Expansion: GSK announced that its Arexvy vaccine received FDA approval to include individuals aged 18 to 49 at elevated risk, marking a significant expansion in the vaccine's applicability in the U.S., which is expected to substantially boost market demand and sales potential.
- Single-Dose Administration: The newly approved single-dose vaccine targets high-risk populations for lower respiratory tract disease caused by RSV, anticipated to improve health outcomes for these individuals and reduce hospitalization rates due to RSV, thereby alleviating the burden on healthcare systems.
- Market Competition: Arexvy is the first RSV vaccine cleared in the U.S., and while Pfizer and Moderna also offer similar products, GSK's successful launch among those aged 60 and older provides a competitive edge that may attract more high-risk younger individuals to vaccination.
- Future Outlook: With the expanded eligibility for Arexvy, GSK may enhance its marketing strategies in future vaccination campaigns to further increase brand awareness and market share, especially in the context of rising demand for RSV vaccines.
See More
Agenus Hosts 2026 Stakeholder Webcast on Immunotherapy Progress
- Immunotherapy Progress: Agenus will host a webcast on March 31, 2026, focusing on the advancements of botensilimab and balstilimab, aiming to enhance treatment options for patients with historically treatment-resistant cancers, showcasing the company's ongoing innovation in immuno-oncology.
- Clinical Data Insights: Chief Medical Officer Steven J. O'Day will discuss the durability and consistency of BOT+BAL across various tumor types, highlighting how these data inform ongoing development and later-stage trials, indicating the company's potential in treating refractory cancers.
- Patient Access Programs: Kamel Djazouli, Head of Medical Affairs, will provide updates on Agenus' global access programs, particularly the AAC and Named Patient Programs in France, demonstrating how the company supports patients with limited treatment options, thereby enhancing its market competitiveness.
- Strategic Priorities: Founder and CEO Garo H. Armen will outline key priorities for 2026, emphasizing the urgency of advancing the BOT+BAL program to improve patient quality of life through innovative treatment solutions.
See More
Agenus Introduces Novel Immunotherapy to Extend Survival
- Innovative Immunotherapy: Agenus announced that preliminary results of the BOT and BAL combination therapy for microsatellite stable colorectal cancer will be presented at the 2026 AACR Annual Meeting, aiming to extend patient survival by reducing reliance on chemotherapy, showcasing the company's cutting-edge exploration in cancer immunotherapy.
- Clinical Trial Expansion: The BBoPCO study is the first trial assessing BOT+BAL in patients without liver, bone, or brain metastases, marking a significant shift towards early application of immunotherapy, which is expected to improve patient response and quality of life, addressing the urgent need for new treatment options.
- Market Demand: Colorectal cancer remains a leading cause of cancer-related deaths globally, with rising incidence among younger populations, and the severe side effects of traditional chemotherapy regimens highlight the critical market significance of introducing new therapies.
- Drug Mechanism: Botensilimab, as an enhanced anti-CTLA-4 antibody, combined with the PD-1 inhibition of balstilimab, aims to activate the immune system targeting traditionally
See More
Agenus Surpasses Earnings and Revenue Expectations
- Earnings Beat: Agenus reported earnings of $0.56 per share, significantly exceeding the Zacks consensus estimate of a loss of $1.27 per share, and improving from a loss of $2.04 per share a year ago, indicating a strong recovery in profitability that is likely to boost investor confidence.
- Significant Revenue Growth: The company posted revenues of $34.2 million for the quarter, surpassing the Zacks consensus estimate of $29.3 million and reflecting a 27.5% increase from $26.84 million a year ago, demonstrating sustained market demand in the biopharmaceutical sector.
- Cautious Future Outlook: Although Agenus has surpassed consensus EPS estimates twice in the past four quarters, management's commentary on future earnings expectations will be crucial for stock price movements; currently, the Zacks Rank is 3 (Hold), suggesting performance may align with the market in the near term.
- Industry Ranking Impact: The Medical - Biomedical and Genetics industry, where Agenus operates, is currently ranked in the bottom 42% by Zacks, which could negatively affect the company's stock performance, prompting investors to monitor overall industry trends for potential impacts on future performance.
See More
Agenus Expands Global Early Access Programs for BOT+BAL
- Expansion of Early Access Programs: Agenus has received over 200 physician inquiries across more than 30 countries, recognizing approximately $4.2 million in initial program revenue, which not only enhances patient treatment opportunities but also strengthens the company's influence in the global market.
- Clinical Data Support: The BOT+BAL combination demonstrated a 42% two-year overall survival and approximately 21 months median survival in heavily pretreated microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients, indicating its potential in difficult-to-treat cancers.
- Initiation of BATTMAN Phase 3 Trial: Agenus has launched the first global Phase 3 registrational trial for the CTLA-4/PD-1 combination in MSS mCRC, expected to enroll 830 patients, aimed at supporting future regulatory submissions and further solidifying its market position.
- Zydus Collaboration Strengthens Infrastructure: The strategic collaboration with Zydus Lifesciences provides Agenus with $91 million in capital and dedicated biologics manufacturing capacity, ensuring clinical development and commercial supply of BOT+BAL, thereby enhancing the company's financial health.
See More
Agenus to Announce Q4 Earnings on March 16
- Earnings Announcement: Agenus (AGEN) is set to release its Q4 2023 earnings on March 16 before market open, with consensus EPS estimate at -$1.30 and revenue estimate at $28.1 million, reflecting a 4.7% year-over-year growth.
- Historical Performance Review: Over the past two years, Agenus has only beaten EPS estimates 25% of the time and revenue estimates 38% of the time, indicating significant volatility in its performance and suggesting investors should proceed with caution.
- Estimate Revision Dynamics: In the last three months, there have been no upward revisions to EPS estimates, with one downward revision, while revenue estimates also saw no upward revisions and two downward revisions, reflecting a cautious market outlook on the company's future performance.
- Collaboration and Expansion: Agenus recently received a $20 million payment under its collaboration with Zydus Life Sciences, highlighting its proactive efforts in global manufacturing expansion and patient access initiatives, which may support future performance.
See More
GSK's Arexvy Vaccine Label Expansion Approved by FDA
- Vaccine Label Expansion: GSK announced that its Arexvy vaccine received FDA approval to include individuals aged 18 to 49 at elevated risk, marking a significant expansion in the vaccine's applicability in the U.S., which is expected to substantially boost market demand and sales potential.
- Single-Dose Administration: The newly approved single-dose vaccine targets high-risk populations for lower respiratory tract disease caused by RSV, anticipated to improve health outcomes for these individuals and reduce hospitalization rates due to RSV, thereby alleviating the burden on healthcare systems.
- Market Competition: Arexvy is the first RSV vaccine cleared in the U.S., and while Pfizer and Moderna also offer similar products, GSK's successful launch among those aged 60 and older provides a competitive edge that may attract more high-risk younger individuals to vaccination.
- Future Outlook: With the expanded eligibility for Arexvy, GSK may enhance its marketing strategies in future vaccination campaigns to further increase brand awareness and market share, especially in the context of rising demand for RSV vaccines.
See More
